160
Participants
Start Date
April 30, 2001
Primary Completion Date
November 30, 2002
Study Completion Date
April 30, 2003
decitabine (5-aza-2'deoxycytidine)
Alta Bates Comprehensive Cancer Center, Berkeley
City of Hope National Medical Center, Duarte
Scripps Clinic, Escondido
Loma Linda Univ. Cancer Center, Loma Linda
Univ. California San Francisco Medical School, San Francisco
University of Florida, Gainesville
H. Lee Moffitt Cancer Center, Tampa
James A. Haley Veteran's Hospital, Tampa
Rush Medical Center, Chicago
University of Illinois at Chicago, Chicago
Dana Farber Cancer Institute, Boston
New England Medical Center Hospital, Boston
University of Massachusetts Medical School, Worcester
VA Medical Center, Minneapolis
Washington Univ. School of Medicine, St Louis
Roswell Park Cancer Institute, Buffalo
Memorial Sloan Kettering Cancer Center, New York
Mount Sinai Medical Center, New York
UNC Lineberger Comprehensive Cancer Center, Chapel Hill
Duke University Medical Center, Durham
The Memphis Cancer Center, Memphis
SW Regional Cancer Center (dba Central Texas Oncology Associates), Austin
Texas Oncology, Dallas
MD Anderson Cancer Center, Houston
Lead Sponsor
Astex Pharmaceuticals, Inc.
INDUSTRY